The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

BUZZ-U.S. STOCKS ON THE MOVE-First Marblehead, Bellicum, OvaScience

Thu, 18th Dec 2014 17:59

(For faster updates on individual market-movers, Eikon usersplease use search string "STXBZ US"; for the Day Aheadnewsletter, http://link.reuters.com/mex49s; for the Morning NewsCall newsletter, http://link.reuters.com/nex49s)U.S. stocks rose on Thursday, with each of the major indexesclimbing more than 1 percent, building on the prior session'srally after the U.S. Federal Reserve's policy statement and oilprices that showed signs of steadying. The Dow Jones industrialaverage rose 0.75 percent, the S&P 500 were up 0.8percent and the Nasdaq Composite were up 1.36 percent.

** FIRST MARBLEHEAD CORP, $5.01, +138.57 pct

The education loan provider said the Internal RevenueService (IRS) has informed the company that it would notchallenge federal tax refunds the company received. IRS proposedin September 2013 to disallow a loss that resulted in the taxrefunds of $176.6 million and $45.1 million.

** BELLICUM PHARMACEUTICALS INC, $27.16, +42.95 pct

The biopharmaceutical company's shares rose as much as 40percent on its debut on Thursday. The company offerd 7.35million shares at $19, above $15-$17 marketed range.

** OVASCIENCE INC, $47.35, +35.44 pct

Wedbush Securities raised its rating on the fertilitytreatment developer to "outperform" from "neutral" after companysaid it will launch 2 fertility products and gave update on theprogress of third treatment.

** SILICON IMAGE INC, $4.98, -26.11 pct

The chipmaker said it expects revenue to fall 10 percent in2015 due to fewer mobile design wins from one its largestcustomers.

** COMSTOCK RESOURCES INC, $5.93, -13.43 pct

The oil and gas producer said it plans to suspend oildrilling in Eagle Ford shale properties in south and east Texasand Tuscaloosa Marine shale in Mississippi as oil prices plunge.

** TETRAPHASE PHARMACEUTICALS INC, $38.2, +15.09pct

The drug developer said its antibiotic to treat complicatedintra-abdominal infections was as effective as Merck & Co Inc's ertapenem in a late-stage study.

** DUNKIN' BRANDS GROUP INC, $42.395, -8.28 pct

The Dunkin' Donuts restaurant operator cut its 2015 forecastfor same-store sales growth in the United States and operatingincome growth, citing slowing sales of packaged coffee in itsrestaurants.

** AGENUS INC, $3.836, +14.51 pct

** GLAXOSMITHKLINE PLC, $43.2, +2.76 pct

The biotechnology company said an experimental vaccineagainst shingles by its partner GlaxoSmithKline met itsgoal in a late-stage study. Agenus will get royalties onpotential commercial sales of the vacine.

** ORACLE INC, $44.53, +8.19 pct

The software maker reported a 3.5 percent increase inquarterly revenue on Wednesday, beating Wall Street'sexpectations, as sales at its closely watched cloud servicesbusiness rose 45 percent.

** KIRBY CORP, $82.1, -7.49 pct

The tank bank operator lowered fourth-quarter earningsestimate to $1.10-$1.20 per share from $1.30-$1.40 per share.The company also lowered its full-year earnings estimate to$4.84 to $4.94 per share from $5.04-$5.14 per share.

** CEPHEID, $53.74, +7.93 pct

Analysts at BofA Merrill Lynch upgraded the biotechnologycompany's stock to "buy" from "neutral". The analysts saidCepheid is poised to gain market share, citing a growing menu ofdiagnostic tests, improved execution with 7,500 placements ofthe company's GeneXpert systems and slow response from itscompetitors.

** WINNEBAGO INDUSTRIES INC, $21.85, -8.39 pct

The maker of motorhomes and camping trailers reported alower-than-expected profit as a shortage of workers at a keyplant in rural Iowa and trouble sourcing key components fromsuppliers stymied production of the company's recreationalvehicles.

** REAL GOODS SOLAR INC, $0.6689, +15.33 pct

The solar company said it won more than 80 contracts toinstall rooftop solar power systems on homes and smallbusinesses. The company said the projects represent more than600kW of solar power.

** ACCENTURE PLC, $89, +4.34 pct

The consulting and outsourcing company raised its revenueforecast for fiscal 2015 after contract wins helped the companypost better-than-expected first-quarter earnings and revenue. The company said it expects revenue growth of 5-8 percent forthe year ending August on a local currency basis, up from the4-7 percent growth it had estimated earlier.

** RITE AID CORP, $6.77, +11.72 pct

The U.S. drugstore chain raised its full-year earningsforecast after cutting it twice this year as higher sales ofprescription drugs pushed up its profit and revenue in the thirdquarter.

** CONAGRA FOODS INC, $36.04, -2.86 pct

The Slim Jim Beef Jerky and Chef Boyardee pasta makerreported quarterly sales that missed estimates due to weakdemand for branded foods and said recovery in itsunder-performing private-label business would take longer thanexpected.

** AK STEEL HOLDING CORP, $6.08, +9.35 pct

The steel maker said it expects fourth-quarter shipments tojump 37 percent compared with the third quarter, helped byacquisitions and strong demand from auto industry.

** THE PANTRY INC, $36.5567, +2.92 pct

Canada's Alimentation Couche-Tard Inc will buysmaller U.S. rival Pantry for about $861 million, a deal thatpositions it as one of the top convenience store operators inNorth America.

** BLACKBERRY LTD, $10.0639, +0.84 pct

The Canadian mobile technology company launched itslong-awaited Classic on Wednesday, a smartphone it hopes willhelp it win back market share and woo those still using olderversions of its physical keyboard devices.

** ZAGG INC, $6.13, +15.01 pct

The mobile accessories maker raised its full-year net salesforecast to $250 million-$255 million from previous range of$225 million-$235 million. The forecast also beat analysts'average estimate of $232.5 million, according to Thomson ReutersI/B/E/S.

** EXXON MOBIL CORP, $90.32, +1.46 pct

** CHEVRON CORP, $108.07, +1.93 pct

** CONOCOPHILLIPS, $68.81, +2.79 pct

** CHESAPEAKE ENERGY CORP, $18.98, +1.61 pct

Oil company stocks rise after Brent crude jumps 3.3percent to above $63/bbl, extending a rebound from 5-year lowsthis week as more energy firms cut investment in new production.

** HERTZ GLOBAL HOLDINGS INC, $22.75, +6.76 pct

Carl Icahn, the rental car company's largest shareholder,raised stake in the company to 11.34 percent from 10.77 percent.Icahn revealed an 8.48 percent stake in Hertz in August; he hassince ousted CEO Mark Frissora and won three board seats at thecompany.

** ALCATEL-LUCENT SA, $3.52, +6.02 pct

** NOKIA, $8.01, +1.91 pct

Two of Europe's top three remaining telecommunicationsequipment companies, Nokia and Alcatel-Lucent, have revivedtalks on a possible merger, Germany's Manager Magazin reportedon Thursday, citing company sources.

** HERMAN MILLER INC, $29.52, -5.08 pct

The furniture maker forecast full-year profit and saleslargely below analysts' estimates. The company also reportedsecond-quarter adjusted profit of 51 cents per share, belowaverage analyst estimate of 52 cents.

** OCWEN FINANCIAL CORP, $20.69, -2.36 pct

The mortgage servicer is facing scrutiny from New York stateand the federal government over whether the company improperlystalled short sales of property to collect more fees, Bloombergreported, citing sources.

** GENWORTH FINANCIAL INC, $7.83, -1.26 pct

The life and mortgage insurer said the review of long termcare insurance active life margins is taking longer thanexpected. The company said it now expects to complete review onor before fourth quarter results in February.

** JABIL CIRCUIT INC, $20.73, +3.29 pct

The company, which makes phone casings for Apple Inc, forecasts second-quarter revenue above estimates,boosted by strong sales of iPhone 6 and 6 Plus. The companyforecast second quarter core earnings of 39-50 cents per share,higher than analysts' average estimate of profit of 38 cents pershare.

** NATIONAL BANK OF GREECE, $1.945, -2.26 pct

The largest Greek bank's U.S.-listed shares down afterfirst-round presidential vote in Greece saw Prime MinisterAntonis Samaras lose by larger-than-expected margin. (Compiled by Anannya Pramanick in Bengaluru; Edited by DonSebastian)

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.